Nyxoah (NASDAQ:NYXH – Get Rating) and Sensus Healthcare (NASDAQ:SRTS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.
Earnings and Valuation
This table compares Nyxoah and Sensus Healthcare’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $3.25 million | 55.33 | -$32.90 million | ($1.26) | -5.72 |
| Sensus Healthcare | $44.53 million | 1.80 | $24.24 million | $1.46 | 3.35 |
Sensus Healthcare has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Analyst Recommendations
This is a summary of recent recommendations and price targets for Nyxoah and Sensus Healthcare, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 0 | 0 | 3 | 0 | 3.00 |
| Sensus Healthcare | 0 | 0 | 3 | 0 | 3.00 |
Nyxoah currently has a consensus target price of $19.67, indicating a potential upside of 172.77%. Sensus Healthcare has a consensus target price of $16.83, indicating a potential upside of 244.24%. Given Sensus Healthcare’s higher probable upside, analysts clearly believe Sensus Healthcare is more favorable than Nyxoah.
Profitability
This table compares Nyxoah and Sensus Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -1,004.67% | -23.03% | -19.15% |
| Sensus Healthcare | 54.44% | 25.11% | 20.68% |
Insider & Institutional Ownership
11.5% of Nyxoah shares are owned by institutional investors. Comparatively, 36.3% of Sensus Healthcare shares are owned by institutional investors. 16.4% of Sensus Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Sensus Healthcare beats Nyxoah on 10 of the 12 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
